Brief: Ultimovacs Provides Update From Phase I Study In Malignant Melanoma

Zelluna ASA

19/06/2023 06:12

June 19 (Reuters) - Ultimovacs ASA  ULTI.OL :
    * ULTIMOVACS PROVIDES 3-YEAR UPDATE FROM PHASE I STUDY IN
MALIGNANT MELANOMA: RESULTS CONFIRM STRONG OVERALL SURVIVAL IN
PATIENTS TREATED WITH  UV1 CANCER VACCINE
    * ALL PATIENTS IN COHORT 2 WHO WERE ALIVE AFTER 2 YEARS
REMAIN
ALIVE AFTER 3 YEARS
    * OBSERVED 67% OVERALL SURVIVAL RATE AT 3-YEAR FOLLOW-UP IN
THIS
PHASE I STUDY

Source text for Eikon:  ID:nGNEbsnN2H 
Further company coverage:  ULTI.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))